Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The TRIAD project has been featured on the HORIZON 2020 website in an article entitled 'Taking targeted autoimmune therapies to the next level.'

The Transplantation Research Immunology Group (TRIG) was a consortium partner in TRIAD, an EU funded project which led to the preclinical development of the novel drug FR104. The drug is now going through clinical trials, leading, it is hoped, to eventual commercialisation.  

Read the full article.